share_log

180 Life Sciences | 8-K: Current report

180 Life Sciences | 8-K: Current report

180 Life Sciences | 8-K:重大事件
美股SEC公告 ·  03/14 08:34

Moomoo AI 已提取核心訊息

180 Life Sciences Corp. has announced that it has regained compliance with the Nasdaq's minimum bid price requirement, as per a notification received from The Nasdaq Stock Market LLC on March 13, 2024. The company's common stock had previously failed to maintain the required minimum bid price of $1.00 over a 30-day period, as stated by Nasdaq Listing Rule 5550(a)(2). However, the closing bid price of the company's common stock has now been at or above $1.00 for 10 consecutive business days. Despite this positive development, 180 Life Sciences remains non-compliant with Nasdaq's minimum stockholders' equity requirement, reporting a stockholders' deficit of ($149,327) for the quarter ended September 30, 2023, which falls short of the Nasdaq Capital Market's requirement of at least $2,500,000 in stockholders' equity. The company is exploring various options to address this issue and is hopeful to regain compliance within the granted period. The press release regarding the regained compliance with the bid price requirement was filed on March 14, 2024.
180 Life Sciences Corp. has announced that it has regained compliance with the Nasdaq's minimum bid price requirement, as per a notification received from The Nasdaq Stock Market LLC on March 13, 2024. The company's common stock had previously failed to maintain the required minimum bid price of $1.00 over a 30-day period, as stated by Nasdaq Listing Rule 5550(a)(2). However, the closing bid price of the company's common stock has now been at or above $1.00 for 10 consecutive business days. Despite this positive development, 180 Life Sciences remains non-compliant with Nasdaq's minimum stockholders' equity requirement, reporting a stockholders' deficit of ($149,327) for the quarter ended September 30, 2023, which falls short of the Nasdaq Capital Market's requirement of at least $2,500,000 in stockholders' equity. The company is exploring various options to address this issue and is hopeful to regain compliance within the granted period. The press release regarding the regained compliance with the bid price requirement was filed on March 14, 2024.
根據納斯達克股票市場有限責任公司於2024年3月13日收到的通知,180生命科學公司宣佈已恢復遵守納斯達克的最低出價要求。根據納斯達克上市規則5550(a)(2)的規定,該公司的普通股此前未能在30天內維持1.00美元的最低出價。但是,該公司普通股的收盤價現已連續10個工作日達到或超過1.00美元。儘管取得了這一積極進展,180 Life Sciences仍未遵守納斯達克的最低股東權益要求,報告稱,截至2023年9月30日的季度股東赤字爲(149,327美元),低於納斯達克資本市場對至少250萬美元股東權益的要求。該公司正在探索各種選擇來解決這個問題,並希望在規定的期限內恢復合規。關於恢復遵守投標價格要求的新聞稿已於2024年3月14日提交。
根據納斯達克股票市場有限責任公司於2024年3月13日收到的通知,180生命科學公司宣佈已恢復遵守納斯達克的最低出價要求。根據納斯達克上市規則5550(a)(2)的規定,該公司的普通股此前未能在30天內維持1.00美元的最低出價。但是,該公司普通股的收盤價現已連續10個工作日達到或超過1.00美元。儘管取得了這一積極進展,180 Life Sciences仍未遵守納斯達克的最低股東權益要求,報告稱,截至2023年9月30日的季度股東赤字爲(149,327美元),低於納斯達克資本市場對至少250萬美元股東權益的要求。該公司正在探索各種選擇來解決這個問題,並希望在規定的期限內恢復合規。關於恢復遵守投標價格要求的新聞稿已於2024年3月14日提交。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息